<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00197015</url>
  </required_header>
  <id_info>
    <org_study_id>208109/231</org_study_id>
    <nct_id>NCT00197015</nct_id>
  </id_info>
  <brief_title>Immunogenicity &amp; Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella &amp; a Varicella Vaccine in Children</brief_title>
  <official_title>Immunogenicity &amp; Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck &amp; Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) &amp; Merck &amp; Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose
      inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a
      varicella (chickenpox) vaccine in children as young as 15 months of age.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open, controlled comparison of Havrix™ administered alone or with MMR II and Varivax™. The
      three groups evaluated are: 1) Havrix™ alone, 2) Havrix™ + MMR II and Varivax™ and 3) MMR II
      and Varivax™ followed by Havrix™ one month later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups.</measure>
    <time_frame>31 days following the second dose of Havrix®</time_frame>
    <description>Concentrations are given as geometric mean concentrations (GMCs) expressed as milli-international units per milliliter (mIU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups</measure>
    <time_frame>31 days following the second dose of Havrix®</time_frame>
    <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per milliliter (mIU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V→HAV Groups</measure>
    <time_frame>42 days following the administration of M-M-R®II and VARIVAX®</time_frame>
    <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 150 milli-international units per milliliter (mIU/mL) for anti-measles antibodies, 28 Effective Dose 50 (ED50) for anti-mumps antibodies and 1:5 for anti-varicella antibodies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V→HAV Groups</measure>
    <time_frame>42 days following administration of M-M-R®II and VARIVAX®</time_frame>
    <description>Vaccine response is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off value assessed include 10 milli-international units per milliliter (mIU/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V→HAV Groups</measure>
    <time_frame>42 days following the administration of M-M-R®II and VARIVAX®</time_frame>
    <description>Titers are given as geometric mean titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups</measure>
    <time_frame>42 days following the first dose of Havrix®</time_frame>
    <description>Concentrations are given as geometric mean concentrations (GMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups</measure>
    <time_frame>42 days following the first dose of Havrix®</time_frame>
    <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V→HAV Group</measure>
    <time_frame>31 days following the second dose of Havrix®</time_frame>
    <description>Concentrations are given as geometric mean concentrations (GMCs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V→HAV Group</measure>
    <time_frame>31 days following the second dose of Havrix®</time_frame>
    <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response to Havrix®</measure>
    <time_frame>31 days following the second dose of Havrix®</time_frame>
    <description>Vaccine response was defined as: 1) a detectable anti-hepatitis A virus (HAV) antibody concentration 31 days following the second dose in subjects who were initially seronegative; and 2) a 2-fold increase in anti-HAV antibody concentrations above the pre-study concentration 31 days following the second dose in subjects who were initially seropositive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 4-day period following each dose of vaccine</time_frame>
    <description>Solicited local symptoms assessed include pain, rash (local), redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms</measure>
    <time_frame>During the 4-day period following each dose of vaccine</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite and rash (general).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events</measure>
    <time_frame>During the 43-day period following each dose of vaccine</time_frame>
    <description>Specific adverse events assessed include papules, vesicles, crusts, parotid/salivary gland swelling and suspected signs of meningitis/febrile seizures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During the 31-day period following each dose of vaccine</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Chronic Illnesses</measure>
    <time_frame>During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)</time_frame>
    <description>New Chronic illnesses include autoimmune disorders, asthma, type I diabetes, allergies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Events</measure>
    <time_frame>During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)</time_frame>
    <description>Medically significant events include, but are not limited to, diabetes, autoimmune disease, asthma, allergies and/or conditions prompting emergency room or physician office visits that are not related to well-child care, vaccination or common acute illnesses (e.g., upper respiratory infection, otitis media, pharyngitis, gastroenteritis, injury and visits for routine physical examination).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1474</enrollment>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>HAV Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAV+MMR+V Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMR+V→HAV Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix®</intervention_name>
    <description>2 doses administered intramuscularly</description>
    <arm_group_label>HAV Group</arm_group_label>
    <arm_group_label>MMR+V→HAV Group</arm_group_label>
    <arm_group_label>HAV+MMR+V Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R®II</intervention_name>
    <description>1 dose administered subcutaneously</description>
    <arm_group_label>MMR+V→HAV Group</arm_group_label>
    <arm_group_label>HAV+MMR+V Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX®</intervention_name>
    <description>1 dose administered subcutaneously</description>
    <arm_group_label>MMR+V→HAV Group</arm_group_label>
    <arm_group_label>HAV+MMR+V Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects whose parents/guardians are believed by the investigator to be willing to
             comply with the requirements of the protocol

          -  A male or female child 12 and 13 months of age at the time of entry into the
             Enrollment Phase

          -  Written informed consent obtained from the parents or guardian of the subject,

          -  Free of obvious health problems as established by medical history and history-directed
             physical examination before entering into the study, and

          -  Parents/guardian of the subject must have a telephone or be able to be contacted by
             telephone

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 42 days preceding the first dose of study vaccine, or planned use
             during the study period, Chronic administration (defined as more than 14 days) of
             immuno-suppressant or other immune-modifying drugs within six months prior to
             vaccination or planned administration at any time during the study period. (For
             corticosteroids, this will mean prednisone, or equivalent, ≥0.5 mg/kg/day. Inhaled,
             nasal and topical steroids are allowed.) Planned administration or administration of
             any vaccine not foreseen by the study protocol during the period 31 days before and 31
             days after each dose of study vaccine(s).

          -  Previous vaccination against hepatitis A,

          -  History of hepatitis A,

          -  Known exposure to hepatitis A,

          -  Previous vaccination against measles, mumps, rubella and/or varicella,

          -  History of measles, mumps, rubella and/or varicella,

          -  Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the
             start of the study,

          -  Planned chronic use of salicylates during the 6-week period following administration
             of the doses of study vaccine(s),

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection,

          -  A family history of congenital, hereditary or infectious immunodeficiency or parental
             risk factors for HIV infection,

          -  History of allergic disease/reactions or hypersensitivity likely to be exacerbated by
             any component of HavrixTM, M-M-RII or VARIVAXTM, including 2-phenoxyethanol, neomycin
             and gelatin,

          -  History of anaphylactic or anaphylactoid reactions to egg proteins,

          -  History of hypersensitivity/allergic reaction to latex. Note: The tip cap and the
             rubber plunger of the HavrixTM needleless pre-filled syringes contain dry natural
             latex rubber.

          -  Major congenital defects or serious chronic illness,

          -  Active untreated tuberculosis,

          -  History of significant blood dyscrasias

          -  History of any neurologic disorder (a history of febrile seizures not associated with
             an underlying neurological disorder does not exclude the subject)

          -  Acute disease at the time of vaccination

          -  Administration of immunoglobulins and/or any blood products within three months prior
             to the first dose of study vaccine or planned administration at any time during the
             entire study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>13 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cabot</city>
        <state>Arkansas</state>
        <zip>72023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waukee</city>
        <state>Iowa</state>
        <zip>50263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sylva</city>
        <state>North Carolina</state>
        <zip>28779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>University Heights</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaver Falls</city>
        <state>Pennsylvania</state>
        <zip>15010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rydal</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205-2489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Rinderknecht S, Michaels MG, Blatter M, Gaglani M, Andrews W, Abughali N, Chandreshekaran V, Trofa AF. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011 Oct;30(10):e179-85. doi: 10.1097/INF.0b013e31822256a5.</citation>
    <PMID>21617573</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>March 11, 2010</results_first_submitted>
  <results_first_submitted_qc>March 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2010</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>208109/231</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>208109/231</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>208109/231</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>208109/231</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>208109/231</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>208109/231</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>While the total numbers of subjects enrolled in the study was 1474, the total number of subjects that entered the study was 1241. The remaining subjects received a subject number but no vaccine dose and were therefore excluded from the analysis and group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HAV Group</title>
          <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
        </group>
        <group group_id="P2">
          <title>MMR+V→HAV Group</title>
          <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
        </group>
        <group group_id="P3">
          <title>HAV+MMR+V Group</title>
          <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="455"/>
                <participants group_id="P3" count="462"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="366"/>
                <participants group_id="P3" count="385"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HAV Group</title>
          <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
        </group>
        <group group_id="B2">
          <title>MMR+V→HAV Group</title>
          <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
        </group>
        <group group_id="B3">
          <title>HAV+MMR+V Group</title>
          <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="324"/>
            <count group_id="B2" value="455"/>
            <count group_id="B3" value="462"/>
            <count group_id="B4" value="1241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.0" spread="0.27"/>
                    <measurement group_id="B2" value="15.0" spread="0.22"/>
                    <measurement group_id="B3" value="15.0" spread="0.25"/>
                    <measurement group_id="B4" value="15.0" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="232"/>
                    <measurement group_id="B4" value="594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="247"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups.</title>
        <description>Concentrations are given as geometric mean concentrations (GMCs) expressed as milli-international units per milliliter (mIU/mL).</description>
        <time_frame>31 days following the second dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V Groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups.</title>
          <description>Concentrations are given as geometric mean concentrations (GMCs) expressed as milli-international units per milliliter (mIU/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V Groups.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1390.4" lower_limit="1186.3" upper_limit="1629.6"/>
                    <measurement group_id="O3" value="1895.2" lower_limit="1682.7" upper_limit="2134.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups</title>
        <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per milliliter (mIU/mL).</description>
        <time_frame>31 days following the second dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups</title>
          <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per milliliter (mIU/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O3" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V→HAV Groups</title>
        <description>Titers are given as geometric mean titers (GMTs).</description>
        <time_frame>42 days following the administration of M-M-R®II and VARIVAX®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV+MMR+V and MMR+V→HAV groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V→HAV Groups</title>
          <description>Titers are given as geometric mean titers (GMTs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV+MMR+V and MMR+V→HAV groups.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="269"/>
                <count group_id="O3" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-measles (n= 269, 301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3218.3" lower_limit="2940.9" upper_limit="3521.8"/>
                    <measurement group_id="O3" value="3136.3" lower_limit="2922.0" upper_limit="3366.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella (n= 269, 304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="88.3" lower_limit="81.9" upper_limit="95.3"/>
                    <measurement group_id="O3" value="76.0" lower_limit="70.7" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-varicella (n= 218, 260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="281.7" lower_limit="246.7" upper_limit="321.8"/>
                    <measurement group_id="O3" value="286.9" lower_limit="252.1" upper_limit="326.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps (n= 244, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="215.7" lower_limit="190.9" upper_limit="243.7"/>
                    <measurement group_id="O3" value="170.3" lower_limit="152.2" upper_limit="190.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups</title>
        <description>Concentrations are given as geometric mean concentrations (GMCs).</description>
        <time_frame>42 days following the first dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups</title>
          <description>Concentrations are given as geometric mean concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V groups.</population>
          <units>milli-international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1" lower_limit="37.9" upper_limit="49.1"/>
                    <measurement group_id="O3" value="43.5" lower_limit="39.3" upper_limit="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups</title>
        <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).</description>
        <time_frame>42 days following the first dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups</title>
          <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV and HAV+MMR+V groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O3" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V→HAV Group</title>
        <description>Concentrations are given as geometric mean concentrations (GMCs).</description>
        <time_frame>31 days following the second dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from MMR+V→HAV Group.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V→HAV Group</title>
          <description>Concentrations are given as geometric mean concentrations (GMCs).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from MMR+V→HAV Group.</population>
          <units>milli-international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1770.3" lower_limit="1569.9" upper_limit="1996.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V→HAV Group</title>
        <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).</description>
        <time_frame>31 days following the second dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from MMR+V→HAV Group.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V→HAV Group</title>
          <description>Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from MMR+V→HAV Group.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response to Havrix®</title>
        <description>Vaccine response was defined as: 1) a detectable anti-hepatitis A virus (HAV) antibody concentration 31 days following the second dose in subjects who were initially seronegative; and 2) a 2-fold increase in anti-HAV antibody concentrations above the pre-study concentration 31 days following the second dose in subjects who were initially seropositive.</description>
        <time_frame>31 days following the second dose of Havrix®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Response to Havrix®</title>
          <description>Vaccine response was defined as: 1) a detectable anti-hepatitis A virus (HAV) antibody concentration 31 days following the second dose in subjects who were initially seronegative; and 2) a 2-fold increase in anti-HAV antibody concentrations above the pre-study concentration 31 days following the second dose in subjects who were initially seropositive.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, rash (local), redness and swelling.</description>
        <time_frame>During the 4-day period following each dose of vaccine</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include pain, rash (local), redness and swelling.</description>
          <population>Analysis was performed on the Total Vaccinated cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="411"/>
                <count group_id="O3" value="419"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (local)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite and rash (general).</description>
        <time_frame>During the 4-day period following each dose of vaccine</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort, on subjects with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite and rash (general).</description>
          <population>Analysis was performed on the Total Vaccinated cohort, on subjects with available data.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="238"/>
                    <measurement group_id="O3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (general)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events</title>
        <description>Specific adverse events assessed include papules, vesicles, crusts, parotid/salivary gland swelling and suspected signs of meningitis/febrile seizures.</description>
        <time_frame>During the 43-day period following each dose of vaccine</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort, on subjects from MMR+V→HAV and HAV+MMR+V groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events</title>
          <description>Specific adverse events assessed include papules, vesicles, crusts, parotid/salivary gland swelling and suspected signs of meningitis/febrile seizures.</description>
          <population>Analysis was performed on the Total Vaccinated cohort, on subjects from MMR+V→HAV and HAV+MMR+V groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Papules</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vesicles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crusts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parotid/salivary gland swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suspected signs of meningitidis/febrile seizures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V→HAV Groups</title>
        <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 150 milli-international units per milliliter (mIU/mL) for anti-measles antibodies, 28 Effective Dose 50 (ED50) for anti-mumps antibodies and 1:5 for anti-varicella antibodies.</description>
        <time_frame>42 days following the administration of M-M-R®II and VARIVAX®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV+MMR+V and MMR+V→HAV groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V→HAV Groups</title>
          <description>Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 150 milli-international units per milliliter (mIU/mL) for anti-measles antibodies, 28 Effective Dose 50 (ED50) for anti-mumps antibodies and 1:5 for anti-varicella antibodies.</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV+MMR+V and MMR+V→HAV groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-measles (n= 250, 268)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="247"/>
                    <measurement group_id="O3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps (n= 197, 212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-varicella (n= 171, 193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V→HAV Groups</title>
        <description>Vaccine response is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off value assessed include 10 milli-international units per milliliter (mIU/mL).</description>
        <time_frame>42 days following administration of M-M-R®II and VARIVAX®</time_frame>
        <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV+MMR+V and MMR+V→HAV groups.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V→HAV Groups</title>
          <description>Vaccine response is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off value assessed include 10 milli-international units per milliliter (mIU/mL).</description>
          <population>Analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, on subjects with available results from HAV+MMR+V and MMR+V→HAV groups.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="246"/>
                    <measurement group_id="O3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</description>
        <time_frame>During the 31-day period following each dose of vaccine</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms</description>
          <population>Analysis was performed on the Total Vaccinated cohort.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="286"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>Analysis was performed on the Total Vaccinated cohort.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Phase (n= 324, 455, 462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended Safety Follow-up Phase (n= 287, 376, 395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Chronic Illnesses</title>
        <description>New Chronic illnesses include autoimmune disorders, asthma, type I diabetes, allergies.</description>
        <time_frame>During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort (for the Active Phase) and the Extended Safety Follow-up cohort (for the Extended Safety Follow-up Phase).</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Chronic Illnesses</title>
          <description>New Chronic illnesses include autoimmune disorders, asthma, type I diabetes, allergies.</description>
          <population>Analysis was performed on the Total Vaccinated cohort (for the Active Phase) and the Extended Safety Follow-up cohort (for the Extended Safety Follow-up Phase).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Phase (n= 324, 455, 462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended Safety Follow-Up Phase (n= 287, 376, 395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Events</title>
        <description>Medically significant events include, but are not limited to, diabetes, autoimmune disease, asthma, allergies and/or conditions prompting emergency room or physician office visits that are not related to well-child care, vaccination or common acute illnesses (e.g., upper respiratory infection, otitis media, pharyngitis, gastroenteritis, injury and visits for routine physical examination).</description>
        <time_frame>During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end)</time_frame>
        <population>Analysis was performed on the Total Vaccinated cohort (for the Active Phase) and the Extended Safety Follow-up cohort (for the Extended Safety Follow-up Phase).</population>
        <group_list>
          <group group_id="O1">
            <title>HAV Group</title>
            <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
          </group>
          <group group_id="O2">
            <title>MMR+V→HAV Group</title>
            <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
          </group>
          <group group_id="O3">
            <title>HAV+MMR+V Group</title>
            <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Events</title>
          <description>Medically significant events include, but are not limited to, diabetes, autoimmune disease, asthma, allergies and/or conditions prompting emergency room or physician office visits that are not related to well-child care, vaccination or common acute illnesses (e.g., upper respiratory infection, otitis media, pharyngitis, gastroenteritis, injury and visits for routine physical examination).</description>
          <population>Analysis was performed on the Total Vaccinated cohort (for the Active Phase) and the Extended Safety Follow-up cohort (for the Extended Safety Follow-up Phase).</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Active Phase (n= 324, 455, 462)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended Safety Follow-Up Phase (n= 287, 376, 395)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Events collected by systematic assessment are reported for subjects with a symptom diary card available.
Events collected by non-systematic method are reported for the Total Vaccinated Cohort</desc>
      <group_list>
        <group group_id="E1">
          <title>HAV Group</title>
          <description>Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)</description>
        </group>
        <group group_id="E2">
          <title>MMR+V→HAV Group</title>
          <description>Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)</description>
        </group>
        <group group_id="E3">
          <title>HAV+MMR+V Group</title>
          <description>Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Dehydratation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mental retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing-related sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="395"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Papules</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="178" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="154" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="187" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="462"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="324"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="462"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

